Form 4: Lixte Biotechnology Director Equity Swap
Statement of Changes in Beneficial Ownership
Director Michael Andrew Holloway exchanged 25,000 stock options for 25,000 fully vested restricted share units.
Summary
- Director Michael Andrew Holloway entered into a Stock Option Cancellation Agreement with Lixte Biotechnology Holdings, Inc. on April 15, 2026.
- The agreement involved the cancellation of 25,000 stock options originally granted on August 15, 2025, with an exercise price of $3.59.
- In exchange, the director received 25,000 restricted share units (RSUs).
- The newly granted RSUs vest immediately upon grant.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- The transaction simplifies the director's equity compensation structure by moving from options to fully vested RSUs.
- Immediate vesting of the 25,000 RSUs provides the director with direct equity ownership.
Negatives
- The cancellation of options removes the potential for future leverage associated with option-based compensation.
Risks
- Equity-based compensation is subject to the underlying market performance of Lixte Biotechnology common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the change in the director's equity holdings.
Management Comments
- The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan.
Industry Context
StockSavvy.ai notes that equity swaps of this nature are common in the biotechnology sector to align director interests with shareholders by converting performance-based options into direct equity, particularly when options are underwater or nearing expiration.
Comparison to Industry Standards
- The conversion of options to RSUs is a standard corporate governance practice to reduce dilution overhang and simplify executive compensation.
- Immediate vesting of director equity is consistent with standard practices for non-employee director compensation in small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation Adjustment | Cancellation of 25,000 options in exchange for 25,000 fully vested RSUs for Director Michael Andrew Holloway. | 04/15/2026 | Neutral; aligns director compensation with current equity value. |
Stakeholder Impact
- Shareholders may see a minor change in the equity structure, but the total number of shares underlying the director's compensation remains unchanged.
Next Steps
- No further actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 08/15/2025 | Original grant date of the canceled stock options. |
| 04/15/2026 | Date of the Stock Option Cancellation Agreement and the grant of 25,000 RSUs. |
| 04/17/2026 | Date of filing the Form 4. |
| 08/15/2030 | Original expiration date of the canceled options. |
Keywords
LIXT, Lixte Biotechnology, Form 4, Insider Trading, Equity Compensation, Restricted Share Units, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.